Pfizer (NYSE:PFE) Rating Reiterated by Cantor Fitzgerald

Pfizer (NYSE:PFE)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $45.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 63.34% from the company’s previous close.

Other analysts also recently issued research reports about the stock. UBS Group decreased their price objective on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research note on Thursday, December 14th. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Barclays cut their price objective on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a report on Thursday, December 14th. Truist Financial cut their price objective on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 14th. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Twelve research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Down 0.6 %

Shares of NYSE:PFE opened at $27.55 on Monday. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer has a 12 month low of $25.61 and a 12 month high of $42.22. The company has a 50-day moving average price of $27.43 and a 200 day moving average price of $29.29. The company has a market cap of $156.00 billion, a price-to-earnings ratio of 76.53, a PEG ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter last year, the firm earned $1.14 EPS. The firm’s revenue for the quarter was down 41.3% compared to the same quarter last year. As a group, equities research analysts predict that Pfizer will post 2.22 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Front Street Capital Management Inc. lifted its position in Pfizer by 4.3% during the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 215 shares during the period. Graves Light Lenhart Wealth Inc. increased its stake in shares of Pfizer by 1.4% during the second quarter. Graves Light Lenhart Wealth Inc. now owns 19,863 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 281 shares in the last quarter. Infrastructure Capital Advisors LLC increased its stake in shares of Pfizer by 5.2% during the second quarter. Infrastructure Capital Advisors LLC now owns 5,751 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 284 shares in the last quarter. Castleview Partners LLC increased its stake in shares of Pfizer by 2.4% during the first quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 287 shares in the last quarter. Finally, United Bank increased its stake in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after purchasing an additional 290 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.